Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells

Cancer Research

Volumn 70, Issue 3, 2010, Pages 906-915

  Biernacki, Melinda A ^a   Marina, Ovidiu ^a   Zhang, Wandi ^a   Liu, Fenglong ^a   Bruns, Ingmar ^c   Cai, Ann ^a   Neuberg, Donna ^a   Canning, Christine M ^a   Alyea, Edwin P ^a,b   Soiffer, Robert J ^a,b   Brusic, Vladimir ^a   Ritz, Jerome ^a,b   Wu, Catherine J ^a,b  

^a Dana Farber Cancer Institute   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYCLOPHOSPHAMIDE; DUAL SPECIFICITY PROTEIN PHOSPHATASE 12; FIBROBLAST GROWTH FACTOR RECEPTOR 4; IMMUNOGLOBULIN; PHOSPHATASE; RAB PROTEIN; RAB38 PROTEIN; TBCE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE LIBRARY; GRAFT VS LEUKEMIA EFFECT; HUMANS; IMMUNITY, HUMORAL; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; RAB GTP-BINDING PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76249127539     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2303     Document Type: Article

References (42)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
3. Wu CJ, Biernacki M, Kutok JL, et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 2005;11:4504-11.
4. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-14.
5. Marina O, Biernacki MA, Brusic V, et al. A concentration-dependent analysis method for high density protein microarrays. J Proteome Res 2008;7:2059-68.
6. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007;21:494-504.
7. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-8.
8. Stegmaier K, Corsello SM, Ross KN, et al. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005;106:2841-8.
9. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-28.
10. Connolly PH, Caiozzo VJ, Zaldivar F, et al. Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol 2004;97:1461-9.
11. Kim CG, Lee JJ, Jung DY, et al. Profiling of differentially expressed genes in human stem cells by cDNA microarray. Mol Cells 2006;21: 343-55.
12. Ge X, Yamamoto S, Tsutsumi S, et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005;86:127-41.
13. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27.
14. Tsai J, Sultana R, Lee Y, et al. RESOURCERER: a database for annotating and linking microarray resources within and across species. Genome Biol 2001;2:SOFTWARE0002.
15. Saeed AI, Bhagabati NK, Braisted JC, et al. TM4 microarray software suite. Methods Enzymol 2006;411:134-93.
16. Lamesch P, Li N, Milstein S, et al. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics 2007;89:307-15.
17. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80.
18. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 2002;9:503-8.
19. Bruns I, Czibere A, Fischer JC, et al. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009;23:892-9.
20. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
21. + CML cells. Blood 2007;109:4016-9.
22. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7.
23. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
24. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
25. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7.
26. Zippelius A, Gati A, Bartnick T, et al. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother 2007;56:249-58.
27. Walton SM, Gerlinger M, de la Rosa O, et al. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NYMEL-1 in melanoma patients. J Immunol 2006;177:8212-8.
28. Jager D, Stockert E, Jager E, et al. Serological cloning of a melanocyte rab guanosine 5′-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. Cancer Res 2000;60:3584-91.
29. Hershkovitz E, Rozin I, Limony Y, et al. Hypoparathyroidism, retardation, and dysmorphism syndrome: impaired early growth and increased susceptibility to severe infections due to hyposplenism and impaired polymorphonuclear cell functions. Pediatr Res 2007;62:505-9.
30. Muda M, Manning ER, Orth K, et al. Identification of the human YVH1 protein-tyrosine phosphatase orthologue reveals a novel zinc binding domain essential for in vivo function. J Biol Chem 1999;274:23991-5.
31. Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther 2006;5:145-9.
32. Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 2007;109:951-3.
33. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8.
34. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947-52.
35. Amigorena S. Fcã receptors and cross-presentation in dendritic cells. J Exp Med 2002;195:F1-3.
36. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007;104:12837-42.
37. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697-702.
38. Scheich F, Duyster J, Peschel C, et al. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 2007;110:2556-60.
39. Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007;67:5489-97.
40. Hirano N, Butler MO, Xia Z, et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006;12:2967-75.
41. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997;90:2529-34.
42. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.